SG&A Expense Trends: Biogen Inc. vs MorphoSys AG

In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Biogen Inc. and MorphoSys AG, two prominent players, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Biogen's SG&A expenses have consistently been higher, peaking in 2021 with a 38% increase from 2014. In contrast, MorphoSys AG, while starting with significantly lower expenses, saw a dramatic rise, especially between 2018 and 2021, with a staggering 1,960% increase. This divergence highlights Biogen's steady investment in administrative functions, while MorphoSys AG's recent surge suggests aggressive expansion or restructuring. These trends offer a window into each company's strategic priorities and market positioning, providing valuable insights for investors and industry analysts alike.